A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Kallyope Inc.

Summary

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: 1. Participant completing an acute treatment trial of elismetrep (Study K-304 P003; attending the EoS Visit 3 within the allowed visit window of the acute treatment study), treated a qualifying migraine in that study, was at least 80% compliant with the daily e-Diary 'check-ins' in the base study and completed the 2-hour and 4-hour post-dose assessments in the eDiary. Note: If a subject treats their qualifying migraine in the base study within 5 days of randomization (i.e. ≤ 4 daily check-ins should have been completed in the eDiary), they are eligible for this study i…

Locations (113)

Central Research Associates, LLC (CRA) dba Flourish Research
Birmingham, Alabama
AMR Mobile
Mobile, Alabama
TrialSphere
Chandler, Arizona
Arkansas Clinical Research
Little Rock, Arkansas
Axiom Research, LLC
Colton, California
ProScience Research Group
Culver City, California

Summary

Eligibility

Interventions

Locations (113)